Brief

"On 30/01/2025", the "European Anti-Fraud Office (OLAF)" issued an update regarding "SHIELD V: Over 3.4 million pills seized in Operation Targeting Counterfeit Medicines". The operation, which marked its fifth consecutive year, involved the coordination of customs authorities from 12 EU Member States, resulting in significant quantities of illicit goods being seized, including counterfeit medicines and medical supplies.

©EU
Press release no 3/2025PDF version Over 3.4 million pills have been seized as part of Operation SHIELD V, in which the European Anti-Fraud Office (OLAF) has played an essential coordinating role. This annual operation targets the misuse and distribution of counterfeit medicines, doping substances, illegal food or sports supplements, and counterfeit COVID-19 medical supplies. In its fifth consecutive year, OLAF facilitated the efforts of the Member States customs authorities in ensuring the integrity of the European market. The coordinated actions of the customs authorities resulted in the seizure of significant quantities of illicit goods, including: 3,4 million pills, over 59.000 packages (sachets, sprays, packs, pens), 1,510 vials (ampoules, flasks) and 272 pieces of medical devices. Joint Effort across 14 Member StatesOperation SHIELD V included the active involvement of customs authorities from 12 EU Member States, namely Austria, Bulgaria, Denmark, Spain, Greece, Croatia, Ireland, Italy, Lithuania, Portugal, Slovenia, Slovakia, and Italy’s Guardia di Finanza. This collaborative effort was further supported by relevant rights holders, ensuring that counterfeit goods were accurately identified and swiftly intercepted. “Traffickers recklessly jeopardise people’s health to turn a quick profit, a reality we cannot ignore. To protect European citizens, cooperation is essential. By combining efforts, OLAF, Europol, and national customs authorities have safeguarded European consumers from dangerous health products,” said Ville Itälä, Director General of OLAF. Operation SHIELD continues to exemplify the importance of coordinated action in tackling illegal activities that endanger public health and undermine legitimate businesses. OLAF’s role ensures that these threats are met with a unified and effective response, safeguarding the health and wellbeing of citizens across the European Union.OLAF mission, mandate and competences:OLAF’s mission is to detect, investigate and stop fraud with EU funds. OLAF fulfils its mission by:• carrying out independent investigations into fraud and corruption involving EU funds, so as to ensure that all EU taxpayers’ money reaches projects that can create jobs and growth in Europe;• contributing to strengthening citizens’ trust in the EU Institutions by investigating serious misconduct by EU staff and members of the EU Institutions;• developing a sound EU anti-fraud policy.In its independent investigative function, OLAF can investigate matters relating to fraud, corruption and other offences affecting the EU financial interests concerning:• all EU expenditure: the main spending categories are Structural Funds, agricultural policy and rural development funds, direct expenditure and external aid;• some areas of EU revenue, mainly customs duties;• suspicions of serious misconduct by EU staff and members of the EU institutions.Once OLAF has completed its investigation, it is for the competent EU and national authorities to examine and decide on the follow-up of OLAF’s recommendations. All persons concerned are presumed to be innocent until proven guilty in a competent national or EU court of law.For further details:Pierluigi CATERINOSpokespersonEuropean Anti-Fraud Office (OLAF)Phone: +32(0)2 29-52335 Email: olaf-mediaec [dot] europa [dot] eu (olaf-media[at]ec[dot]europa[dot]eu)https://anti-fraud.ec.europa.euLinkedIn: European Anti-Fraud Office (OLAF)If you’re a journalist and you wish to receive our press releases in your inbox, please leave us your contact data.

Details

Publication date30 January 2025AuthorEuropean Anti-Fraud Office

News typeOLAF press release

Highlights content goes here...

Purpose:

The European Anti-Fraud Office (OLAF) has announced the success of Operation SHIELD V, a coordinated effort to combat the misuse and distribution of counterfeit medicines, doping substances, illegal food or sports supplements, and counterfeit COVID-19 medical supplies. This operation is a key example of OLAF’s mission to detect, investigate, and stop fraud with EU funds.

Effects on Industry:

The seizure of over 3.4 million pills, 59,000 packages, 1,510 vials, and 272 pieces of medical devices has significant implications for the pharmaceutical industry. The operation highlights the importance of coordinated action in tackling illegal activities that endanger public health and undermine legitimate businesses. This demonstrates the need for companies to strengthen their supply chain security and implement effective measures to prevent counterfeit goods from entering the market.

Relevant Stakeholders:

The success of Operation SHIELD V affects various stakeholders, including:

  • European citizens who are protected from dangerous health products
  • Pharmaceutical companies that must strengthen their supply chain security to prevent counterfeit goods
  • Customs authorities in 14 EU Member States that collaborated on this operation
  • Relevant rights holders who supported the effort to identify and intercept counterfeit goods

Next Steps:

To comply with or respond to this update, stakeholders should:

  • Review their supply chain security measures to prevent counterfeit goods from entering the market
  • Strengthen collaboration with customs authorities and other relevant bodies to tackle illegal activities that endanger public health
  • Implement effective measures to ensure the integrity of the European market

Any Other Relevant Information:

This operation is part of OLAF’s mission to detect, investigate, and stop fraud with EU funds. The success of Operation SHIELD V demonstrates the importance of coordinated action in tackling illegal activities that endanger public health and undermine legitimate businesses. This highlights the need for continued collaboration between customs authorities, relevant rights holders, and other stakeholders to protect European citizens from dangerous health products.

European Anti-Fraud Office (OLAF)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies